Sodium-glucose cotransporter-2 inhibitors and the risk of lung cancer among patients with type 2 diabetes: a retrospective cohort study
Shapiro, S. B.; Yin, H.; Yu, O. H. Y.; Azoulay, L.
Show abstract
ObjectiveTo determine whether the use of sodium-glucose cotransporter 2 (SGLT-2) inhibitors, compared to dipeptidyl peptidase 4 (DPP-4) inhibitors, is associated with a decreased risk of incident lung cancers among patients with type 2 diabetes. MethodsWe assembled a new-user, active comparator cohort of SGLT-2 inhibitor and DPP-4 inhibitor users using the United Kingdom Clinical Practice Research Datalink. We fit Cox proportional hazards models with propensity score fine stratification weighting to estimate hazard ratios (HRs) with 95% confidence intervals (CI) for incident lung cancers. ResultsCrude lung cancer incidence rates were 0.92 and 1.37 per 1,000 person-years among 47,517 SGLT-2 inhibitor and 129,807 DPP-4 inhibitor users, respectively. No reduced risk of lung cancer was observed among SGLT-2 inhibitor users after weighting (HR 1.08, 95% CI 0.78-1.48). Conclusions: In this large cohort study, the use of SGLT-2 inhibitors was not associated with a decreased risk of lung cancer.
Matching journals
The top 10 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Effect of common maintenance drugs on the risk and severity of COVID-19 in elderly patients 91%
- Safety and effectiveness of RBD-specific polyclonal equine F(ab′)2 fragments for the treatment of hospitalized patients with severe Covid-19 disease: a retrospective cohort study 90%
- Investigating the added value of biomarkers compared with self-reported smoking in predicting future e-cigarette use: Evidence from a longitudinal UK cohort study 90%
Similar papers in this journal
- Using quantitative bias analysis to adjust for misclassification of COVID-19 outcomes: An applied example of inhaled corticosteroids and COVID-19 outcomes 91%
- Emulating randomized controlled trials of long-acting insulins and cardiovascular events using real-world data for patients with type 2 diabetes 88%
- Bias amplification of unobserved confounding in pharmacoepidemiological studies using indication-based sampling: there is no free lunch in restricting the sample to those with a particular drug-indication 88%
Similar papers in this journal
- A comprehensive assessment of statin discontinuation among patients who concurrently initiate statins and CYP3A4-inhibitor drugs; a multistate transition model 91%
- Statin treatment effectiveness and the SLCO1B1 *5 reduced function genotype: long-term outcomes in women and men 91%
- People exposed to proton pump inhibitors shortly preceding COVID-19 diagnosis are not at an increased risk of subsequent hospitalizations and mortality: a nation-wide matched cohort study 90%
Similar papers in this journal
- The protective effect of club cell secretory protein (CC-16) on COPD risk and progression: a Mendelian randomisation study 90%
- Early Lenzilumab Treatment Of COVID-19 Patients Using C-Reactive Protein As A Biomarker Improves Efficacy: Results From The Phase 3 ‘Live-Air’ Trial 89%
- Current tobacco smoking and risk from COVID-19: results from a population symptom app in over 2.4 million people 88%
Similar papers in this journal
- Effect of smoking on drug-resistant tuberculosis treatment outcomes and potential mechanistic pathways: A multicountry cohort study 90%
- Risk factors for asthma-related hospital and intensive care admissions in children, adolescents, and adults: a cohort study using primary and secondary care data 89%
- Relative Contributions of Family History and a Polygenic Risk Score on COPD and Related Outcomes: COPDGene and ECLIPSE studies 88%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.